Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

Table 5

Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast after stratification by body mass index (BMI).

IGFBP-2; (µIU/mL)	Co/Ca	Model 1 OR^a	Model 2 OR^b	Co/Ca	Model 3 OR^c
Normal BMI (<25 kg/m^2)
Q1	8/9	1.0^Ref.	1.0^Ref.	8/8	1.0^Ref.
Q2	17/18	0.97 (0.29–3.18)	1.27 (0.36–4.51)	16/18	1.50 (0.40–5.61)
Q3	18/28	1.36 (0.42–4.41)	1.99 (0.55–7.26)	18/28	2.49 (0.65–7.22)
Q4	36/34	0.79 (0.25–2.46)	1.52 (0.42–5.52)	36/34	1.37 (0.37–4.99)
Trend		0.42	0.72		0.89
Overweight/obese (≥25 kg/m^2)
Q1	60/68	1.0^Ref.	1.0^Ref.	55/63	1.0^Ref.
Q2	51/51	0.89 (0.52–1.52)	1.19 (0.67–2.14)	44/46	1.22 (0.67–2.25)
Q3	51/49	0.82 (0.48–1.37)	1.02 (0.57–1.82)	48/45	0.95 (0.53–1.73)
Q4	32/16	0.40 (0.19–0.84)	0.46 (0.19–1.08)	32/16	0.43 (0.18–1.04)
Trend		0.02	0.10		0.05

Model 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m²).
Model 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
Model 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.